Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Stock Has Average Price Target of $4.00

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) has been assigned a consensus recommendation of “Hold” from the seven brokerages that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $4.00.

Several analysts have issued reports on the company. Weiss Ratings upgraded Werewolf Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 10th. Wall Street Zen raised Werewolf Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd. Finally, Zacks Research raised Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, October 5th.

Werewolf Therapeutics Price Performance

Werewolf Therapeutics stock opened at $0.99 on Friday. The firm has a market capitalization of $47.92 million, a PE ratio of -1.30 and a beta of 0.51. The company’s 50-day moving average is $0.97 and its 200-day moving average is $0.68. Werewolf Therapeutics has a fifty-two week low of $0.27 and a fifty-two week high of $1.43.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its earnings results on Friday, July 31st. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.36. The firm had revenue of $21.00 million during the quarter, compared to the consensus estimate of $21.00 million. As a group, analysts expect that Werewolf Therapeutics will post -0.89 EPS for the current year.

Institutional Trading of Werewolf Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of HOWL. Covestor Ltd bought a new position in Werewolf Therapeutics in the 3rd quarter valued at about $124,000. Vontobel Holding Ltd. bought a new stake in shares of Werewolf Therapeutics during the third quarter worth approximately $55,000. Vilga Financial Planning LLC bought a new stake in shares of Werewolf Therapeutics during the third quarter worth approximately $49,000. Squarepoint Ops LLC bought a new stake in shares of Werewolf Therapeutics during the second quarter worth approximately $37,000. Finally, Bank of America Corp DE acquired a new position in shares of Werewolf Therapeutics in the second quarter valued at approximately $112,000. Institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer treatments that stimulate the immune system. The company’s approach is designed to activate immune responses within the tumor microenvironment while limiting exposure to healthy tissues.

Werewolf’s technology platform, known as INDUKINE, uses conditionally activated cytokines. These therapeutic proteins are intended to remain inactive in the bloodstream and become activated primarily in tumors, where they may help recruit and enhance immune cells to attack cancer.